Hannah M. Seagle

Hannah M. Seagle

Auto-generated profile, based on publicly available information

Hannah M. Seagle

Vanderbilt University Genetics Institute, Department of Medicine, Vanderbilt University, Nashville, TN, USA; Joseph Maxwell Cleland Atlanta VA Medical Center, Atlanta, GA, USA; Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AHAndreana Holowatyj
Andreana Holowatyj
WWWanqing Wen
Wanqing Wen
TGTimothy Gibbs
Timothy Gibbs
HSHannah M. Seagle
Hannah M. Seagle
SKSamantha R. Keller
Samantha R. Keller
XGXingyi Guo
Xingyi Guo
Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities. Significance: NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients. See related commentary by Shen et al., p. 530 . This article is highlighted in the In This Issue feature, p. 517

10 September 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HSHannah M. Seagle
Hannah M. Seagle
SKSamantha R. Keller
Samantha R. Keller
STSean V. Tavtigian
Sean V. Tavtigian
CHCarolyn Horton
Carolyn Horton
AHAndreana Holowatyj
Andreana Holowatyj
PURPOSE: The early-onset colorectal cancer (EOCRC) burden differs across racial/ethnic groups, yet the role of germline genetic predisposition in EOCRC disparities remains uncharacterized. We defined the prevalence and spectrum of inherited colorectal cancer (CRC) susceptibility gene variations among patients with EOCRC by race and ethnicity. PATIENTS AND METHODS: We included individuals diagnosed with a first primary CRC between age 15 and 49 years who identified as Ashkenazi Jewish, Asian, Black, Hispanic, or White and underwent germline genetic testing of 14 CRC susceptibility genes performed by a clinical testing laboratory. Variant comparisons by racial and ethnic groups were evaluated using chi-square tests and multivariable logistic regression adjusted for sex, age, CRC site, and number of primary colorectal tumors. RESULTS: Among 3,980 patients with EOCRC, a total of 530 germline pathogenic or likely pathogenic variants were identified in 485 individuals (12.2%). By race/ethnicity, 12.7% of Ashkenazim patients, 9.5% of Asian patients, 10.3% of Black patients, 14.0% of Hispanic patients, and 12.4% of White patients carried a germline variant. The prevalence of Lynch syndrome ( P = .037), as well as APC, CHEK2, MLH1, monoallelic MUTYH, and PTEN variants, varied by race/ethnicity among patients with EOCRC (all P < .026). Ashkenazim and Hispanic patients had significantly higher odds of presenting with a pathogenic APC variant, which included p.I1307K (odds ratio [OR], 2.67; 95% CI, 1.30 to 5.49; P = .007) and MLH1 variant (OR, 8.69; 95% CI, 2.68 to 28.20; P = .0003), respectively, versus White patients in adjusted models. CONCLUSION: Germline genetic features differed by race/ethnicity in young patients with CRC, suggesting that current multigene panel tests may not be representative of EOCRC risk in diverse populations. Further study is needed to optimize genes selected for genetic testing in EOCRC via ancestry-specific gene and variant discovery to yield equitable clinical benefits for all patients and to mitigate inequities in disease burden.

7 August 2025 in The American Journal of Human Genetics
Verified
Journal Article
Open access
HSHannah M. Seagle
Hannah M. Seagle
AAAlexis T. Akerele
Alexis T. Akerele
JDJoseph A. DeCorte
Joseph A. DeCorte
JHJacklyn N. Hellwege
Jacklyn N. Hellwege
JBJoseph H. Breeyear
Joseph H. Breeyear
MVMarijana Vujkovic
Marijana Vujkovic
Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving the treatment of diseases. We employed a cross-disciplinary approach to identify potential therapeutics for the prevention of metabolic-dysfunction-associated steatotic liver disease (MASLD) in at-risk individuals by using humans as a model organism. We identified 212 putative candidate genes associated with MASLD by using data from a large multi-ancestry genetic association study, of which 158 (74.5%) were previously unreported. From this set, we identified 57 genes that encode for druggable protein targets and for which the effects of increasing genetically predicted gene expression on MASLD risk align with the function of that drug on the protein target. We then used We then evaluated these potential targets for evidence of efficacy by using Mendelian randomization, pathway analysis, and protein structural modeling. Through these approaches, we present compelling evidence to suggest that the activation of FADS1 by icosapent ethyl, as well as S1PR2 by fingolimod, could be a promising therapeutic strategy for MASLD prevention.

21 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
HSHannah M. Seagle
Hannah M. Seagle
AAAlexis T. Akerele
Alexis T. Akerele
JDJoseph A. DeCorte
Joseph A. DeCorte
JHJacklyn N. Hellwege
Jacklyn N. Hellwege
JBJoseph H. Breeyear
Joseph H. Breeyear
MVMarijana Vujkovic
Marijana Vujkovic
Summary: Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving treatment of diseases. We employed a cross-disciplinary approach to identify potential treatments for metabolic dysfunction associated steatotic liver disease (MASLD) using humans as a model organism. We identified 212 putative causal genes associated with MASLD using data from a large multi-ancestry genetic association study, of which 158 (74.5%) are novel. From this set we identified 57 genes that encode for druggable protein targets, and where the effects of increasing genetically predicted gene expression on MASLD risk align with the function of that drug on the protein target. These potential targets were then evaluated for evidence of efficacy using Mendelian randomization, pathway analysis, and protein structural modeling. Using these approaches, we present compelling evidence to suggest activation of FADS1 by icosopent ethyl as well as S1PR2 by fingolimod could be promising therapeutic strategies for MASLD.

11 December 2025
Verified
Other
Open access
AHAndreana Holowatyj
Andreana Holowatyj
WWWanqing Wen
Wanqing Wen
TGTimothy Gibbs
Timothy Gibbs
HSHannah M. Seagle
Hannah M. Seagle
SKSamantha R. Keller
Samantha R. Keller
XGXingyi Guo
Xingyi Guo
Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities.Significance:NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients.See related commentary by Shen et al., p. 530.This article is highlighted in the In This Issue feature, p. 517

11 December 2025
Verified
Other
Open access
AHAndreana Holowatyj
Andreana Holowatyj
WWWanqing Wen
Wanqing Wen
TGTimothy Gibbs
Timothy Gibbs
HSHannah M. Seagle
Hannah M. Seagle
SKSamantha R. Keller
Samantha R. Keller
XGXingyi Guo
Xingyi Guo
Table S1. Clinical and demographic characteristics of the colorectal cancer (CRC) patient study population by race/ethnicity and age at sequencing: AACR Project GENIE.Table S2. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with early-onset and late-onset nonhypermutated colorectal cancer. Genes ranked by false discovery rate (FDR).Table S3. Racial/ethnic patterns in baseline mutation probability, comparison and heterogeneity of all non-silent somatic gene mutations among patients with early-onset and late-onset non-hypermutated colorectal cancer.Table S4. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with earlyonset and late-onset non-hypermutated colorectal cancer by sex.Table S5. Read depth for clinical-grade targeting sequencing data from tumor tissues and case counts by early-onset and late-onset groups and sequencing center. Figure S1. Mutation rates among 6,903 tumor samples from colorectal cancer patients across racial/ethnic groups.Figure S2. Adjusted mutation rates in 653 hypermutated colorectal tumors: AACR GENIE.Figure S3. Tumor mutational burden (TMB) across sequencing assay/platform for early-onset and late-onset non-hypermutated colorectal cancer cases: AACR Project GENIE.Figure S4. Frequency of non-silent somatic mutations in commonly assayed and mutated genes between early-onset and late-onset non-hypermutated CRC cases (mutation frequency >10%).